Selpercatinib’s role in treating RET fusion-positive pancreatic neuroendocrine carcinoma exemplifies the merging of targeted therapy with digital health tools, signifying a shift toward more adaptive, patient-focused oncological care, and emphasizing the importance of digital biomarkers in monitoring and improving treatment outcomes. The gene discussed is RET; the disease is pancreatic endocrine carcinoma.